DOCSLIB.ORG

Corporate Responsibility Report Summary 2013

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Corporate Responsibility Report Summary 2013 Corporate Responsibility Report Summary 2013 “ Alongside other interventions, an effective vaccine could really help reduce the burden of malaria for Africa.” Corporate Responsibility Report Summary 2013 1 About GSK Our mission Cover image GSK’s mission is to improve the Nahya Salim, a paediatrician and research scientist in Tanzania, Africa, has been quality of human life by enabling working on GSK’s RTS,S malaria vaccine trials at the Ifakara Health Institute people to do more, feel better, since 2007. She is currently overseeing trials of the new live longer. We are doing this by vaccine, as well as researching how malaria interacts with other diseases, such as developing innovative products intestinal worms, TB and HIV. and improving access to healthcare for patients around the world. This summary contains highlights from External recognition our performance across the four areas of our responsible business approach: Topped the biannual Access Became first company to be Achieved Bronze ranking in Health for all to Medicines Index since it awarded global certification to RobecoSAM’s 2014 Our Behaviour began in 2008 (the next index the Carbon Trust’s Water Sustainability Yearbook (based Our People is in 2014). REDUCING WATER Standard in recognition of our on 2013 submission), putting Our Planet YEAR ON YEAR year-on-year reductions in us in the top 10% The only healthcare company operational water use globally. of our industry. to be included in the CDP Your feedback counts Performance Leadership Index We welcome your feedback on our and the CDP Disclosure Member of FTSE4Good since Narrowly missed inclusion of responsible business performance and Leadership Index in 2013. 2004. the Dow Jones Sustainability reporting. Please contact us at Ranking in 2013 with a score [email protected]. You can also request of 81. to receive regular updates on our progress. Note to SB. Please keep coloured gradient on the buttons for both normal and rollover actions please. Corporate Responsibility Report Summary 2013 2 CEO’s statement As a global healthcare company, GSK can play an important role in meeting societal challenges. In 2013, we continued to develop innovative life-saving drugs Message from our CEO and work with partners to get medicines to the people that need them most. In 2013, we made new commitments to In 2013, we donated our four billionth tablet Our continued commitment to transparency increase transparency of our clinical of albendazole to treat intestinal worms and was also evident in our efforts to disclose research by announcing our support for the lymphatic filariasis – part of our long-term and address our environmental impacts. AllTrials campaign and becoming the first commitment to tackle neglected tropical We are the only healthcare company listed pharmaceutical company to commit to diseases – and delivered 862 million vaccine in both the CDP’s Disclosure Leadership publishing the detailed clinical study reports doses worldwide. We also strengthened our Index and its Performance Leadership Index for all of our medicines. In May, we were the global initiatives to tackle non-communicable in 2013, for our clear reporting and first in our industry to launch an online diseases such as cancer, diabetes, performance on climate impacts. system enabling researchers to request respiratory and heart disease. access to anonymised patient-level data My job as CEO is to deliver a healthy from our clinical trials. I am pleased that I am also delighted we achieved a company, and that is only possible with Over the past six years we have been some other companies have now also significant milestone for our malaria vaccine healthy employees. Our ground breaking making fundamental changes to deliver adopted this approach. candidate which demonstrated that it could Partnership for Prevention initiative will give innovation and access to our products potentially halve the number of malaria benefits-eligible employees and their for patients and customers, and improved We also announced plans to evolve the way cases in young children. This vaccine has families equal access to preventive and sustainable financial performance for we sell and market products to healthcare the potential to save hundreds of thousands basic healthcare benefits wherever they are our shareholders. professionals, to further align our activities of childrens’ lives and we plan to file for based. with the interests of patients and remove approval during 2014. We are committed to 2013 was the most productive period of even the perception of conflict of interest. making it available at a not-for-profit price. In 2014, we will continue to challenge our R&D output in the company’s history. Of the Specifically, we plan to stop direct business model at every level, to ensure we six major new medicine files we profiled at payments to healthcare professionals for There is no higher priority for me than the are responding to the needs of patients and the start of 2013, five were approved and speaking engagements and for attendance values-based conduct of our employees. meeting the wider expectations of society. we are expecting regulatory decisions for at medical conferences, and extend our US In the past few years, we have focused the remaining asset in this group in the first ‘Patient First’ programme globally, to on bringing to life our values and being half of 2014. In addition, we launched our decouple sales team remuneration from thoughtful about what they really mean new injectable quadrivalent flu vaccine in scrip generation. at a human level. the USA. Together, these new drugs offer patients a range of new treatment options We continue to expand access to our It is because of my strong belief in our and represent substantial opportunities for medicines to people living in the company’s values that the allegations made business growth. developing world. in China about the behaviour of some individuals were so disappointing. The Sir Andrew Witty We continue to take action to reform our During 2013, we signed a ground-breaking investigation into this matter by the Chief Executive Officer business model to meet the expectations of five-year partnership with Save the Children, authorities in China continues and we are society and deliver our mission, in line with to combine the resources and capabilities cooperating fully. As a company, we are our values. of our two organisations to help save the committed to learning the lessons and lives of one million children living in the taking all necessary action in relation to poorest countries in Africa. the outcome of this investigation. Note to SB. Please keep coloured gradient on the buttons for both normal and rollover actions please. Corporate Responsibility Report Summary 2013 3 Who we are GSK is a science-led global healthcare company that researches and manufactures a range of products to help people do more, feel better and live longer. As a global healthcare company, our Pharmaceuticals Vaccines Consumer healthcare commercial success depends on creating innovative new medicines, vaccines and healthcare products, and making these accessible to as many people who need them as possible. By doing this, we will be able to grow our business and provide benefits to patients, consumers, society, our employees and our shareholders. We put our values at the heart of every decision we make, and we commit to help £17.9bn 67% £3.4bn 13% £5.2bn 20% people do more, feel better, live longer. Turnover of Group Turnover of Group Turnover of Group We develop and make medicines to treat a Our vaccines business is one of the largest in We develop and market a range of broad range of conditions including: the world, producing more than 30 vaccines consumer health products based on respiratory disease, cancer, heart disease, for children and adults against a range of scientific innovation. We have brands in four bacterial and viral infections such as HIV, infectious diseases. In 2013, we delivered main categories: Total wellness, Oral care, lupus and skin conditions. 860 million vaccine doses, over 80% of them Nutrition and Skin health. for use in developing countries. Our values are Where we are Employees by region 2013 (%) Turnover by region 2013 (%) transparency, respect We have a significant global commercial 3 presence in more than 150 markets, with a 3 7 for people, integrity and 17 network of 86 manufacturing sites 7 £26.5bn 33 patient focus. worldwide, and R&D centres in the UK, USA, 2013 Group turnover Spain, Belgium and China. 38 25 39 28 USA USA Europe Europe EMAP EMAP Japan Japan Other Other Note to SB. Please keep coloured gradient on the buttons for both normal and rollover actions please. Corporate Responsibility Report Summary 2013 4 How we create value We are adapting our business model and pursuing a strategy that delivers sustainable performance through innovation and expanding access, driven by our values. Our mission Our strategic priorities – grow, deliver, Our business model Outputs We have a challenging and inspiring simplify – help us work towards our vision, We have a broadly-based and balanced Delivering innovation and maximising mission: to improve the quality of human life while enhancing business performance and business across pharmaceuticals, vaccines access to our products generates value by enabling people to do more, feel better, delivering sustainable growth. and consumer healthcare. At the core of our for patients, and society more widely. live longer. This mission gives us the business model are the concepts of innovation purpose to develop innovative medicines We focus on understanding the needs of and access. We create value by researching Our primary contribution is to make and products, and make them available to as patients, consumers and individual markets and manufacturing innovative and high products that provide benefits to patients many people who need them as possible.
Load more

Recommended publications
  • Leapfrogging Africa Sustainable Innovation in Health, Education and Agriculture
    Berlin Institute for Population and Development Leapfrogging Africa Sustainable Innovation in Health, Education and Agriculture hen in Rwanda bring in blood reserves +++ sustainable intensification makes farming more productive +++ online teaching not only during the pandemic +++ avoidable infectious diseases +++ kanian solutions +++ top school +++ development reduces the number of children +++ avoiding the mistakes of industrialized countries +++ central development areas: health, education and agriculture +++ Leapfrogging in Africa +++ higher yields +++ Diagnosis out of About the Berlin Institute The Berlin Institute for Population and Development is an independent think tank that deals with issues of regional and global demographic change. The Institute was founded in 2000 as a non-profit foundation and has the task of raising awareness of demographic change, promoting sustainable development, introducing new ideas into politics and developing concepts for solving demographic and development policy problems. In its studies, discussion and background papers, the Berlin Institute prepares scientific information for the political decision-making process. Further information, as well as the possibility to subscribe to the free regular newsletter “Demos”, can be found at www.berlin-institut.org. Support the independent work of the Berlin Institute. The Berlin Institute receives no public institutional support whatsoever. Project funding, research contracts, donations and endowments make the successful work of the Institute possible. The Berlin Institute is recognized as a non-profit organization. Donations and endowments are tax deductible. The Friends of the Berlin Institute brings together interested and committed individuals, companies and foundations who are willing to support the Berlin Institute financially and with ideas. You can find information about the Supporters’ Association at http://www.berlin-institut.org/foerderkreis-des-berlin-instituts.html.
    [Show full text]
  • TRANSLATING RECOMMENDATIONS INTO ACTION FIRST PROGRESS REPORT on IMPLEMENTATION of RECOMMENDATIONS November 2011–June 2012
    Commission on information and accountability for Women’s and Children’s Health TRANSLATING RECOMMENDATIONS INTO ACTION FIRST PROGRESS REPORT ON IMPLEMENTATION OF RECOMMENDATIONS November 2011–June 2012 Commission on information and accountability for Women’s and Children’s Health TRANSLATING RECOMMENDATIONS INTO ACTION FIRST PROGRESS REPORT ON IMPLEMENTATION OF RECOMMENDATIONS November 2011–June 2012 This is a preliminary report covering activities that have been carried out since November 2011, when the Strategic Workplan for Accountability (strategic workplan) was endorsed in a stake­ holders’ meeting in Ottawa, co­hosted by the Government of Canada and WHO. Working groups were formed to implement the strategic workplan. The first few months of work focused on institutional accountability processes by establishing national frameworks and global support activities. Results will become more apparent in the course of the upcoming implementation year. This report is prepared to inform the independent Expert Review Group for its progress report to the United Nations Secretary­General. © World Health Organization 2012 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e­mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Tanzania National Institute for Medical Research TANZANIA Leonard Mboera
    ALIGNMENT AND HARMONISATION IN HEALTH RESEARCH COHRED Council on Health Research for Development Gabriela Montorzi Sylvia de Haan Carel IJsselmuiden Tanzania National Institute for Medical Research TANZANIA Leonard Mboera An assessment of the health research system A country report of the AHA series Council on Health Research for Development (COHRED) ALIGNMENT AND HARMONISATION IN HEALTH RESEARCH COHRED TANZANIA An assessment of the health research system A country report of the AHA series Council on Health Research for Development Gabriela Montorzi Sylvia de Haan Carel IJsselmuiden Tanzania National Institute for Medical Research Leonard Mboera Council on Health Research for Development (COHRED) Acknowledgements We are grateful to all our collaborators for contributing in different ways to the successful completion of this study. Thanks are due to: • NACCAP for providing the financial support for this study. • All stakeholders interviewed, for their availability and valuable contribution to the understanding of the Tanzania Health Research System. • Donor agency headquarters for validating financial data and contributing with financial information. Keywords Alignment and harmonisation, national health research systems, Tanzania, Canada, Denmark, Ireland, The Netherlands, Norway, Sweden, Switzerland, United Kingdom, Paris declaration on aid effectiveness, research financing ISBN 92-9226-034-0 Copyright and Fair Use The Council on Health Research for Development (COHRED) holds the copyright to its publications and web pages but encourages duplication and dissemination of these materials for non-commercial purposes. Proper citation is requested and modification of these materials is prohibited. Permission to make digital or hard copies of part or all of this work for personal or classroom use is granted without fee and without a formal request provided that copies are not made or distributed for profit or commercial purposes and that copies bear this notice and full citation on the first page.
    [Show full text]
  • Ethical Implications of Malaria Vaccine Development
    Institute of Biomedical Ethics and History of Medicine, University of Zurich Director: Prof. Dr. med. Dr. phil. Nikola Biller-Andorno ______________________________________________________________________ Dissertation under the supervision of Prof. Dr. med. Dr. phil. Nikola Biller-Andorno and Prof. Dr. phil. Marcel Tanner Ethical Implications of Malaria Vaccine Development INAUGURAL-DISSERTATION To receive the title of (Dr. sc. med./PhD) awarded by the Faculty of Medicine University of Zurich submitted by Machteld van den Berg Dissertation committee: Prof. Dr. med. Dr. phil. Nikola Biller-Andorno (chair and main supervisor) Prof. Dr. phil. Marcel Tanner (co-supervisor) PD Dr. med. et sc. nat. Sonja Merten This dissertation has been accepted by the Medical Faculty, University of Zurich upon request of Prof. Dr. Dr. Nikola Biller- Andorno Zurich 2019 Publication record These dissertation chapters have been published/submitted in/to the following journals: 1. RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials Machteld van den Berg, Bernhards Ogutu, Nelson Sewankambo, Nikola Biller-Andorno, Marcel Tanner Published: May 2019 Journal: BMC Trials 2. Clinical trials in low-resource settings: the perspectives of caregivers of paediatric participants from Uganda, Tanzania and Kenya Machteld van den Berg, Bernhards Ogutu, Nelson Sewankambo, Sonja Merten, Nikola Biller-Andorno, Marcel Tanner Published: June 2019 Journal: Tropical Medicine & International Health 3. Applying complexity theory to model
    [Show full text]
  • 5.09 Otras Ciencias Sociales
    CONICYT Ranking por Disciplina > Sub-área OECD (No Académicas) Comisión Nacional de Investigación 5. Ciencias Sociales > 5.9 Otras Ciencias Sociales Científica y Tecnológica PAÍS INSTITUCIÓN RANKING PUNTAJE FRANCE Centre National de la Recherche Scientifique (CNRS) 1 5,000 USA University of Illinois Chicago Hospital 2 5,000 GERMANY Max Planck Society 3 5,000 TAIWAN Academia Sinica - Taiwan 4 5,000 CANADA Centre for Addiction & Mental Health - Canada 5 5,000 USA Centers for Disease Control & Prevention - USA 6 5,000 USA VA Boston Healthcare System 7 5,000 ITALY Consiglio Nazionale delle Ricerche (CNR) 8 5,000 CHINA Chinese Academy of Sciences 9 5,000 SPAIN Consejo Superior de Investigaciones Cientificas (CSIC) 10 5,000 NORWAY Institute of Transport Economics 11 5,000 USA National Bureau of Economic Research 12 5,000 RUSSIA Russian Academy of Sciences 13 5,000 ARGENTINA Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) 14 5,000 CZECH REPUBLIC Czech Academy of Sciences 15 5,000 FRANCE Institut National de la Sante et de la Recherche Medicale (Inserm) 16 5,000 USA Microsoft 17 5,000 USA National Institutes of Health (NIH) - USA 18 5,000 USA Research Triangle Institute 19 5,000 USA Atlanta VA Health Care System 20 5,000 USA US Department of Veteran Affairs 21 5,000 NETHERLANDS Academic Medical Center Amsterdam 22 5,000 USA New York State Psychiatry Institute 23 5,000 GERMANY IZA Institute Labor Economics 24 5,000 GERMANY Helmholtz Association 25 5,000 ROMANIA Romanian Academy of Sciences 26 5,000 UNITED KINGDOM NERC Natural
    [Show full text]
  • Comparison of Clinical Trials in the Industrialized World and Africa Christian Burri; Swiss Tropical and Public Health Institute
    Life Science Forum Basel 2010 Comparison of Clinical Trials in the industrialized world and Africa Christian Burri; Swiss Tropical and Public Health Institute Department of Medicines Research Basel, 23rd June 2010 Comparison of Clinical Trials in the industrialized world and Africa Life Science Forum Basel PD Dr. Christian Burri Head of Department Swiss Tropical & Public Health Institute The Swiss TPH … … is an associated institute of the University of Basel … has the mandate to contribute to the improvement of the health of populations internationally and nationally through excellence in research, services, and teaching & training at the levels of innovation, validation & application … has over 500 staff from 40 nations thereof ~100 PhD students 1 Life Science Forum Basel 2010 Comparison of Clinical Trials in the industrialized world and Africa Christian Burri; Swiss Tropical and Public Health Institute Swiss Tropical & Public Health Institute The Swiss TPH … … the Swiss Tropical Institute (STI) was founded in 1943 as a public organisation based on a local government act … became the “Swiss Tropical and Public Health Institute” (Swiss TPH) at the beginning of the year 2010 after the integration of the Institute of Social & Preventive Medicine (ISPM) of the University of Basel … is supported at ~20 % by the Swiss Federal Government & Canton of Basel- Stadt … earns the greater part of funding through competitively acquired project funds and the earnings of the Service Departments Agenda • Contribution by the Swiss Tropical & Public Health
    [Show full text]
  • 14Th Annual RBM VCWG Meeting Moevenpick Hotel Route De Pré
    14th Annual RBM VCWG Meeting Moevenpick hotel Route de Pré Bois 20, 1215 Geneva, Switzerland 30 January - 1 February 2019 Participants list # Family name First name Name of the employer Country Email 1 Aawi Agnidoufeyi Ministry of Health Togo [email protected] 2 Abdelhamid Elmahdi Muzamil Institute of Endemic Diseases, University of Khartoum Sudan [email protected] 3 Abebe Aklilu Seyoum Abt Associates United States of America [email protected] 4 Abeku Tarekegn Malaria Consortium United Kingdom [email protected] 5 Achee Nicole University of Notre Dame United States of America [email protected] 6 Adey Richard Adey Business Development GmbH Austria [email protected] 7 Agyei Samuel Asiedu Anglogold Ashanti Malaria Control Ltd. Ghana [email protected] 8 Ahmed Ayman University of Khartoum Sudan [email protected] 9 Aidenagbon Godwin Chemonics Nigeria [email protected] 10 Akim Ikupa Swiss Tropical and Public Health Institute Tanzania [email protected] 11 Akogbeto Codjo Martin Ministry of Health Benin [email protected] 12 Ali Abdullah Ministry of Health Tanzania Zanzibar [email protected] 13 Alssada Methaq National Malaria Control Programme Yemen [email protected] 14 Alvarez Ana Unitaid Switzerland [email protected] 15 Ameneshewa Birkinesh World Health Organization Republic of the Congo [email protected] 16 Arruti Errasti Begoña Goizper Group Spain [email protected] 17 Asiedu Samuel Anglogold Ashanti Malaria Control Ltd. Ghana [email protected] 18 Assan Malik Kof Anglogold Ashanti Malaria Control Ltd. Ghana [email protected] 19 Atta-Obeng Christian National Malaria Control Programme Ghana [email protected] 20 Baldini Francesco University of Glasgow United Kingdom [email protected] 21 Barasa Sheila Clinton Health Access Initiative Kenya [email protected] 22 Baud Francis Clariant Plastics & Coatings Ltd.
    [Show full text]
  • Alliance for Case Studies for Global Health
    Case Studies for Global Health Building relationships. Sharing knowledge. Alliance for Case Studies for Global Health ® www.casestudiesforglobalhealth.org Case Studies for Global Health Building relationships. Sharing knowledge. Case Studies for Global Health Case Studies for Global Health: Building relationships. Sharing knowledge. ISBN #0-9778444-8-X Copyright ©2009 by the Alliance for Case Studies for Global Health The logos of the Bill & Melinda Gates Foundation, International AIDS Vaccine Institute (IAVI), Association of University Technology Managers (AUTM), Global Health Progress and TDR are the trademark of the respective organizations. All rights reserved. This material may be quoted or reproduced without charge for noncommercial purposes only; please acknowledge source. This publication does not imply endorsement by the Alliance for Case Studies for Global Health of any product or service, nor any organization, corporation or institution. Case Studies for Global Health is available in electronic format and limited print copies are available. You may download a copy of the book or individual case studies at: www.casestudiesforglobalhealth.org. All other inquiries: Managing Editor Alliance for Case Studies for Global Health 111 Deer Lake Road, Suite 100 Deerfield, IL 60015 USA Web site: www.casestudiesforglobalhealth.org E-mail: [email protected] Printed in the USA on FSC-certified paper. Methods and Acknowledgement This publication is an initiative of the Alliance for Case Studies We reached out to many universities, organizations, companies for Global Health, a collaboration of the Association of University and governments to identify potential case studies. To capture as Technology Managers (AUTM), the Bill & Melinda Gates many diverse stories as possible, we published a call for case studies Foundation, Global Health Progress, the International AIDS in various newsletters, journals and on Web sites during the fall Vaccine Initiative (IAVI) and Tropical Disease Research (TDR).
    [Show full text]
  • A Case Study of the Uganda National Minimum Healthcare Package
    Regional Network for DISCUSSION Equity in Health in east Paper and southern Africa NO. 110110 A case study of the Uganda National Minimum Healthcare Package Dr. Isaac Kadowa Ministry of Health, Uganda In association with Ifakara Health Institute and Training and Research Support Centre In the Regional Network for Equity in Health in east and southern Africa (EQUINET) EQUINET DISCUSSION PAPER 110 The role of Essential Health Benefits in the delivery of integrated services: Learning from practice in East and Southern Africa August 2017 With support from IDRC (Canada) Table of contents Executive summary ............................................................................................................................. 2 1. Background ................................................................................................................................... 4 1.1 Context ............................................................................................................................................................. 4 1.2 Health, morbidity and mortality profile ..................................................................................................... 4 1.3 Organisation of health system ................................................................................................................... 5 2. Methods for the case study: ........................................................................................................... 8 3. Development of the essential health benefit ..............................................................................
    [Show full text]
  • 2015 Global Go to Think Tank Index Report
    University of Pennsylvania ScholarlyCommons Think Tanks and Civil Societies Program TTCSP Global Go To Think Tank Index Reports (TTCSP) 2-9-2016 2015 Global Go To Think Tank Index Report James G. McGann University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/think_tanks Part of the International and Area Studies Commons McGann, James G., "2015 Global Go To Think Tank Index Report" (2016). TTCSP Global Go To Think Tank Index Reports. 10. https://repository.upenn.edu/think_tanks/10 2016 Copyright: All rights reserved. No part of this report may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by information storage or retrieval system, without written permission from the University of Pennsylvania, Think Tanks and Civil Societies Program. All requests, questions and comments should be sent to: James G. McGann, Ph.D. Senior Lecturer, International Studies Director Think Tanks and Civil Societies Program The Lauder Institute University of Pennsylvania Telephone: (215) 746-2928 Email: [email protected] This paper is posted at ScholarlyCommons. https://repository.upenn.edu/think_tanks/10 For more information, please contact [email protected]. 2015 Global Go To Think Tank Index Report Abstract Background The Think Tanks and Civil Societies Program (TTCSP) at the University of Pennsylvania conducts research on the role policy institutes play in governments and civil societies around the world. Often referred to as the “think tanks’ think tank,” TTCSP examines the evolving role and character of public policy research organizations. Over the last 25 years, the TTCSP has developed and led a series of global initiatives that have helped bridge the gap between knowledge and policy in critical policy areas such as international peace and security, globalization and governance, international economics, environmental issues, information and society, poverty alleviation, and healthcare and global health.
    [Show full text]
  • Grand Challenges Canada, Funded by the Government of Canada, Today Announced $2.4 Million in Grants for 22 Bold Ideas to Address This Challenge
    News Release September 22, 2014 Saving “Every Woman, Every Child”: Canada ‘Incubates’ 22 Bold New Ideas Innovators worldwide receive seed grants to * Help Bangladesh garment workers express, store breast milk * Assist with childbirths in remote areas via mobile telecommunications * Stabilize vaccines without refrigeration * Produce snacks from rice bran waste to fight children’s iron deficiency Toronto, Canada – On the eve of United Nations General Assembly events focussed on ways to save and improve the lives of mothers, newborns and children, Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in grants for 22 bold ideas to address this challenge. The novel approaches include: ● A program for Bangladeshi mothers working in garment factories to express, pasteurize and store breast milk -- thereby improving infant nutrition, reducing absenteeism due to child illnesses, and lowering baby formula expense ● A clever new hand-pump device design to help struggling newborns take a first breath ● A low-cost, portable system for diagnosing child pneumonia in high-altitude Peru ● A program to train traditional midwives in the Peruvian Amazon to use smart phones to collect information from pregnant women and to schedule antenatal care delivered by medical river ships ● A snack produced from rice bran waste to combat child iron deficiency ● Using chicken feathers to make a universally-affordable, effective mosquito net ● A technique for safely storing vaccines at room temperature -- considered a holy grail of global health -- by applying a novel polymer coating ● A portable ultrasound imaging device to help medical professionals oversee childbirths in remote areas via cellular telecommunications. Seed funding of $112,000 is offered to each of eight projects based in Canada (Edmonton, Hamilton, Toronto and Sudbury) that will be implemented in the developing world, and to 11 projects from innovators based in low- and middle-income countries (Bangladesh, India, Kenya, Tanzania and Uganda).
    [Show full text]
  • 2019 Global Go to Think Tank Index Report
    University of Pennsylvania ScholarlyCommons Think Tanks and Civil Societies Program TTCSP Global Go To Think Tank Index Reports (TTCSP) 6-18-2020 2019 Global Go To Think Tank Index Report James G. McGann University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/think_tanks Part of the International and Area Studies Commons McGann, James G., "2019 Global Go To Think Tank Index Report" (2020). TTCSP Global Go To Think Tank Index Reports. 17. https://repository.upenn.edu/think_tanks/17 2020 Copyright: All rights reserved. No part of this report may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by an information storage or retrieval system, without written permission from the University of Pennsylvania, Think Tanks and Civil Societies Program. All requests, questions and comments should be sent to: James G. McGann, Ph.D. Senior Lecturer, International Studies Director Think Tanks and Civil Societies Program The Lauder Institute University of Pennsylvania Email: [email protected] This paper is posted at ScholarlyCommons. https://repository.upenn.edu/think_tanks/17 For more information, please contact [email protected]. 2019 Global Go To Think Tank Index Report Abstract The Think Tanks and Civil Societies Program (TTCSP) of the Lauder Institute at the University of Pennsylvania conducts research on the role policy institutes play in governments and civil societies around the world. Often referred to as the “think tanks’ think tank,” TTCSP examines the evolving role and character of public policy research organizations. Over the last 29 years, the TTCSP has developed and led a series of global initiatives that have helped bridge the gap between knowledge and policy in critical policy areas such as international peace and security, globalization and governance, international economics, environmental issues, information and society, poverty alleviation, and healthcare and global health.
    [Show full text]